This product is in development. If you are interested in this product, please contact us directly. We will accelerate our R&D process according to your needs and reserve the product for you.
Cat. No. / Size
Price
Availability
Qty
IL2-M52H5-100ug
$350.00
IL2-M52H5-1mg
$2,310.00
Sub-Total:
$ 0
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources

分子别名(Synonym)

ILDR2,C1orf32

表达区间及表达系统(Source)

Mouse ILDR2, His Tag (IL2-M52H5) is expressed from human 293 cells (HEK293). It contains AA Leu 36 - Glu 201 (Accession # B5TVM2-1).

Predicted N-terminus: Leu 36

蛋白结构(Molecular Characterization)

Online-Res(Leu 36 - Glu 201) B5TVM2-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 20.5 kDa.

内毒素(Endotoxin)

制剂(Formulation)

Please contact us for detailed information.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

Background

ILDR2 belongs to the immunoglobulin superfamily. May be involved in lipid homeostasis and ER stress pathways. ILDR2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer.